
Azitra brings in Series A to advance microbiome skin therapies
The Connecticut company is developing microbiome therapeutics to treat skin conditions like eczema, rashes caused by cancer treatment and Netherton, a chronic, orphan disease.
The Connecticut company is developing microbiome therapeutics to treat skin conditions like eczema, rashes caused by cancer treatment and Netherton, a chronic, orphan disease.
More funding and another powerful pharma backer have entered the microbiome space, showing that at least some investors and pharma execs believe the field can begin converting preclinical ideas into valid human therapies.